MX2012007332A - Agonistas de mglu2. - Google Patents

Agonistas de mglu2.

Info

Publication number
MX2012007332A
MX2012007332A MX2012007332A MX2012007332A MX2012007332A MX 2012007332 A MX2012007332 A MX 2012007332A MX 2012007332 A MX2012007332 A MX 2012007332A MX 2012007332 A MX2012007332 A MX 2012007332A MX 2012007332 A MX2012007332 A MX 2012007332A
Authority
MX
Mexico
Prior art keywords
agonists
mglu2
mglu2 agonists
novel
schizophrenia
Prior art date
Application number
MX2012007332A
Other languages
English (en)
Spanish (es)
Inventor
James Allen Monn
Lourdes Prieto
Lorena Taboada Martinez
Carlos Montero Salgado
Bruce William Shaw
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012007332(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2012007332A publication Critical patent/MX2012007332A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2012007332A 2009-12-21 2010-12-15 Agonistas de mglu2. MX2012007332A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
PCT/US2010/060371 WO2011084437A1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (1)

Publication Number Publication Date
MX2012007332A true MX2012007332A (es) 2012-07-20

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007332A MX2012007332A (es) 2009-12-21 2010-12-15 Agonistas de mglu2.

Country Status (35)

Country Link
US (1) US8318184B2 (enExample)
EP (1) EP2516406B1 (enExample)
JP (1) JP5779190B2 (enExample)
KR (1) KR101395356B1 (enExample)
CN (1) CN102695701B (enExample)
AR (1) AR079343A1 (enExample)
AU (1) AU2010340039B2 (enExample)
BR (1) BR112012017188B1 (enExample)
CA (1) CA2784667C (enExample)
CR (1) CR20120322A (enExample)
CY (1) CY1114880T1 (enExample)
DK (1) DK2516406T3 (enExample)
DO (1) DOP2012000173A (enExample)
EA (1) EA020229B1 (enExample)
EC (1) ECSP12011989A (enExample)
ES (1) ES2435651T3 (enExample)
HN (1) HN2012001160A (enExample)
HR (1) HRP20131052T1 (enExample)
IL (1) IL220011A (enExample)
JO (1) JO2978B1 (enExample)
MA (1) MA33824B1 (enExample)
MX (1) MX2012007332A (enExample)
MY (1) MY160618A (enExample)
NZ (1) NZ600305A (enExample)
PE (1) PE20121688A1 (enExample)
PH (1) PH12012501253A1 (enExample)
PL (1) PL2516406T3 (enExample)
PT (1) PT2516406E (enExample)
RS (1) RS53063B (enExample)
SG (1) SG181836A1 (enExample)
SI (1) SI2516406T1 (enExample)
TN (1) TN2012000281A1 (enExample)
TW (1) TWI477490B (enExample)
UA (1) UA107684C2 (enExample)
WO (1) WO2011084437A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3533797B1 (en) 2010-02-17 2023-12-20 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
KR101598679B1 (ko) 2011-06-17 2016-02-29 일라이 릴리 앤드 캄파니 mGlu2 수용체 효능제로서의 비시클로(3.1.0)헥산-2,6-디카르복실산 유도체
AR089718A1 (es) 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
PL3096790T3 (pl) * 2014-01-21 2020-01-31 Janssen Pharmaceutica, N.V. Kombinacje zawierające pozytywne modulatory allosteryczne lub agonistów ortosterycznych metabotropowego receptora glutaminergicznego podtypu 2 i ich zastosowanie
NZ735973A (en) 2015-04-01 2023-06-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
US7256217B2 (en) * 2001-01-11 2007-08-14 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
HRP20041179B1 (hr) * 2002-06-11 2012-11-30 Eli Lilly And Company Prekursorski oblici lijekova za aminokiseline s pobuđivačkom aktivnosti
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
CN103209954B (zh) * 2010-11-18 2015-09-02 伊莱利利公司 作为mGluR2/3拮抗剂的4-取代的-3-苄氧基-双环[3.1.0]己烷化合物
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3

Also Published As

Publication number Publication date
BR112012017188A8 (pt) 2016-10-04
AU2010340039A1 (en) 2012-08-09
US8318184B2 (en) 2012-11-27
MA33824B1 (fr) 2012-12-03
HRP20131052T1 (hr) 2013-12-06
JO2978B1 (en) 2016-03-15
PE20121688A1 (es) 2012-12-05
BR112012017188A2 (pt) 2016-03-22
JP5779190B2 (ja) 2015-09-16
SI2516406T1 (sl) 2013-11-29
ES2435651T3 (es) 2013-12-20
BR112012017188B1 (pt) 2021-06-22
IL220011A (en) 2014-03-31
MY160618A (en) 2017-03-15
EA020229B1 (ru) 2014-09-30
NZ600305A (en) 2014-01-31
US20110152334A1 (en) 2011-06-23
TN2012000281A1 (en) 2013-12-12
HN2012001160A (es) 2015-08-24
CN102695701A (zh) 2012-09-26
KR20120094056A (ko) 2012-08-23
PL2516406T3 (pl) 2014-03-31
EP2516406B1 (en) 2013-09-18
HK1171228A1 (en) 2013-03-22
EA201290558A1 (ru) 2012-12-28
ECSP12011989A (es) 2012-07-31
CA2784667C (en) 2014-11-18
TW201144290A (en) 2011-12-16
JP2013514974A (ja) 2013-05-02
IL220011A0 (en) 2012-07-31
AU2010340039B2 (en) 2014-03-20
PT2516406E (pt) 2013-10-10
EP2516406A1 (en) 2012-10-31
DOP2012000173A (es) 2012-11-30
WO2011084437A1 (en) 2011-07-14
AR079343A1 (es) 2012-01-18
CY1114880T1 (el) 2016-12-14
DK2516406T3 (da) 2013-10-14
RS53063B (sr) 2014-04-30
UA107684C2 (xx) 2015-02-10
KR101395356B1 (ko) 2014-05-14
TWI477490B (zh) 2015-03-21
CR20120322A (es) 2012-07-10
PH12012501253A1 (en) 2014-08-01
CA2784667A1 (en) 2011-07-14
CN102695701B (zh) 2014-10-01
SG181836A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
TN2012000281A1 (en) Mglu2 agonists
TN2011000673A1 (en) Bace inhibitors
PH12012501355A1 (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
PH12013500500A1 (en) Fused heteroaryls and their uses
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
MX2012008141A (es) Compuestos y metodos.
CR10955A (es) Nuevo procedimiento de sintesis de la agomelatina
MY161473A (en) Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
CR10960A (es) Nuevo procedimiento de sintesis de la agomelatina
MX2012005155A (es) Compuestos de quinazolina.
CR10934A (es) Nuevo procedimiento de sintesis de la agomelatina
UA38601U (en) 2,2'-dithioxo-4,4'-dioxo-[5,5']-bithiazolidinyl-idene-diyl-3,3'-dibutanoic acid diarylamides having antitumor activity
CY1117682T1 (el) Παραγωγα δικυκλο(3.1.0)εξανο-2,6-δικαρβοξυλικου οξεος ως αγωνιστης του υποδοχεα mglu2
UA79655U (en) Compounds n-para-methoxyphenyl-3-(7'-theophylline-8'-bromo)-succinimide and n-ortho-methoxyphenyl-3-(7'-theophylline-8with potential physiological properties
UA35938U (en) 1-phenyl-o-tolylamino-1,5-dihydropyrrol-2-one having antioxidant activity
UA42812U (ru) Использование мази тиотриазолина в качестве агента, обладающего фотопротекторными свойствами
TN2010000583A1 (en) Organic compounds
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
UA41660U (en) Use of jacton and mexidol as actoprotector
UA64452U (ru) Применение гена аполипопротеида Е (апоЕ) в качестве средства для профилактики кардиосклероза
UA44978U (en) 2,8-dimethyl-3-dymethylaminomethylquinolione-4-on possessing anxiolytic and antiamnestic activities
CL2009001553S1 (es) Mesa.

Legal Events

Date Code Title Description
FG Grant or registration